Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR6 | P43657 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670276 | 1.00 | LPAR6 (0.35) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL14643062 | 0.87 | LPAR6 (0.38) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL7777378 | 0.84 | — | — | |
| SCHEMBL7776041 | 0.83 | TSHR (0.41) | LPAR1LPAR2LPAR3ALDH1A1TSHR | |
| SCHEMBL6658678 | 0.82 | ALDH1A1 (0.46) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL4847179 | 0.82 | MEN1 (0.35) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL14000853 | 0.82 | ALDH1A1 (0.33) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL7771270 | 0.82 | ALDH1A1 (0.33) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL10592766 | 0.81 | LPAR1 (0.55) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL14642724 | 0.80 | LPAR1 (0.39) | LPAR6LPAR1LPAR4LPAR5LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136037-A1 | DEUTERIUM-ENRICHED RUBOXISTAURIN | PROTIA, LLC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136037-A1 | DEUTERIUM-ENRICHED RUBOXISTAURIN | RDX, HRH3, QDPR | LPAR6 4125/4885LPAR1 4254/4885LPAR4 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.